Core Viewpoint - Flywire Corporation is facing a class action lawsuit due to allegations of misleading statements regarding its revenue growth and the impact of visa-related restrictions on its business [3][4]. Group 1: Class Action Details - The class action represents investors who purchased Flywire securities between February 28, 2024, and February 25, 2025, with a deadline of September 23, 2025, to file a lead plaintiff motion [1]. - The Portnoy Law Firm is offering complimentary case evaluations to investors seeking to recover losses [2]. Group 2: Allegations Against Flywire - The lawsuit claims that Flywire overstated the strength and sustainability of its revenue growth [3]. - It is alleged that the negative effects of permit and visa-related restrictions on Flywire's business were understated [3]. Group 3: Financial Performance - On February 25, 2025, Flywire reported a loss per share of $0.12, missing consensus estimates by $0.12, and revenue of $117.6 million, which was $1.25 million below expectations [4]. - The CFO disclosed that revenue in Canada and Australia was expected to decline over 30% year-over-year due to policy changes and new visa rules, with similar challenges anticipated in the U.S. market [4]. - Following the announcement, Flywire's stock price fell by more than 37% [4].

Core Viewpoint - Snap Inc. is facing a class action lawsuit due to allegations of misleading investors regarding its advertising revenue and growth potential during the specified class period from April 29, 2025, to August 5, 2025 [1][3]. Group 1: Class Action Details - The class action lawsuit represents investors who purchased Snap securities during the class period and have until October 20, 2025, to file a lead plaintiff motion [1]. - The lawsuit claims that Snap's management created a false impression of reliable advertising revenue information while attributing uncertainties to external macroeconomic conditions [3]. Group 2: Allegations and Financial Impact - The complaint alleges that Snap's optimistic statements about advertising growth were unfounded and based on execution capabilities that the company was failing to meet [3]. - On August 5, 2025, Snap reported disappointing second quarter 2025 financial results, revealing a sharp slowdown in advertising revenue, which led to a stock price drop of more than 17% [4].

Group 1 - The Portnoy Law Firm is advising investors of Vestis Corporation regarding a class action lawsuit for those who purchased securities between May 2, 2024, and May 6, 2025 [1][2] - The lawsuit alleges that Vestis misled investors by presenting false information about its revenue forecasts and growth projections while downplaying risks related to seasonality and economic conditions [3] - On May 7, 2025, Vestis withdrew its full-year 2025 revenue and growth guidance, leading to a stock price drop of over 37% after the announcement of disappointing third-quarter forecasts [4] Group 2 - Vestis provides uniform rental services and workplace supplies across the United States and Canada [2] - The company claimed a return to positive growth in fiscal 2025, which was later deemed unfounded as it faced a substantial decline in revenue from existing customers [3] - The firm attributed its disappointing results to "lost business exceeding new business" and cited an "increasingly uncertain macro environment" as a reason for withdrawing its outlook [4]

Core Viewpoint - The Portnoy Law Firm is representing investors in a class action lawsuit against Vestis Corporation, alleging misleading information regarding revenue forecasts and growth projections during the specified class period [1][3]. Group 1: Class Action Details - The class action represents investors who purchased securities between May 2, 2024, and May 6, 2025, with a deadline of August 8, 2025, to file a lead plaintiff motion [1]. - The lawsuit claims that Vestis misled investors by presenting an overly optimistic outlook while downplaying risks associated with seasonality and economic conditions [3]. Group 2: Allegations and Company Performance - Vestis is accused of creating a false impression of reliable revenue forecasts, which ultimately led to a significant decline in revenue from existing customers [3]. - On May 7, 2025, Vestis withdrew its full-year 2025 revenue guidance and issued third-quarter forecasts that missed market expectations, attributing the disappointing results to "lost business exceeding new business" and an "increasingly uncertain macro environment" [4]. - Following the announcement of these results, Vestis' stock price fell by more than 37% [4].

Core Viewpoint - Lockheed Martin Corporation is facing a class action lawsuit due to alleged false statements and failures to disclose critical information that resulted in significant financial losses for investors during the specified class period from January 23, 2024, to July 21, 2025 [1][3][4]. Group 1: Allegations Against Lockheed Martin - The lawsuit claims that Lockheed Martin lacked effective internal controls over risk-adjusted contracts, impacting the accuracy of profit reporting [5]. - It is alleged that the company did not have adequate review procedures for program requirements, technical complexities, schedules, and risks [5]. - Lockheed Martin is accused of overstating its ability to fulfill contract commitments, particularly regarding cost, quality, and schedule [5]. - The lawsuit suggests that these failures made it likely for Lockheed Martin to report significant financial losses [5]. Group 2: Financial Impact and Stock Price Reactions - On October 22, 2024, Lockheed Martin announced an $80 million loss on a classified program, leading to a stock price drop of over 6% [5]. - A January 28, 2025 announcement revealed pre-tax losses of $1.7 billion, causing the stock price to decline by more than 9% [5]. - Following a July 22, 2025 announcement of an additional $1.6 billion in pre-tax losses, Lockheed Martin's stock price fell nearly 11% [5].

Core Viewpoint - A class action lawsuit has been initiated against Vestis Corporation, alleging that the company misled investors regarding its revenue forecasts and growth projections during the specified class period from May 2, 2024, to May 6, 2025 [1][3]. Group 1: Allegations and Misleading Information - The lawsuit claims that Vestis created a false impression of having reliable information to support its optimistic revenue forecasts while downplaying risks associated with seasonality and broader economic conditions [3]. - Vestis' claims of returning to positive growth in fiscal 2025 were deemed unfounded, as the company experienced a significant decline in revenue from existing customers, contradicting its growth projections [3]. Group 2: Financial Impact and Stock Performance - On May 7, 2025, Vestis withdrew its full-year 2025 revenue and growth guidance, issuing third-quarter forecasts that significantly missed market expectations [4]. - The company attributed its disappointing results to "lost business exceeding new business" and cited an "increasingly uncertain macro environment" as reasons for the withdrawal of its outlook, leading to a stock price drop of over 37% [4].

Core Viewpoint - A class action lawsuit has been filed against 3D Systems Corporation, alleging that the company made misleading statements regarding its financial health and the impact of customer spending on its business [3][4]. Financial Performance - 3D Systems reported a Q4 non-GAAP loss of $0.19 per share, missing consensus estimates by $0.08 [6] - Q4 revenue was $111 million, representing a 3.4% year-over-year decline and falling short of expectations by $4.17 million [6] - Full-year revenue for 2024 was $440.1 million, a 10% decline year-over-year attributed to lower hardware sales and macroeconomic challenges [6] - The company experienced a $9 million revenue reduction in Q4 due to revised accounting estimates for its Regenerative Medicine Program [6] - In Q1 2025, revenue was $94.5 million, an 8% year-over-year decline, and below the consensus estimate of $99.5 million [6] - The net loss for Q1 2025 was $37 million (or $0.28 per share), more than double the $16 million loss in Q1 2024 [6] - An adjusted loss of $0.21 per share was reported, worse than the expected $0.14 loss [6] - The adjusted EBITDA was negative at $23.9 million, compared to a $20.1 million loss in Q1 2024 [6] Class Action Details - The class action lawsuit covers investors who purchased securities between August 13, 2024, and May 12, 2025 [1] - Investors have until August 12, 2025, to file a lead plaintiff motion [1] - The lawsuit claims that 3D Systems failed to disclose the negative impact of weakened customer spending and changes in its partnership with United Therapeutics Corporation [3]

Core Viewpoint - Fortrea Holdings Inc. is facing a class action lawsuit for allegedly misleading investors regarding its financial projections and business model following its spin-off from Labcorp [1][3][4]. Company Overview - Fortrea is a global clinical research organization (CRO) that assists in the development of pharmaceutical and medical device products. It was spun off from Labcorp in June 2023 and had ongoing long-term projects at that time [3]. Allegations of Misleading Information - The lawsuit claims that Fortrea overestimated the revenue from its Pre-Spin Projects for 2025, overstated cost savings from phasing out transition service agreements (TSAs), and inflated its EBITDA targets for 2025, presenting an overly optimistic view of its post-spin-off business model [5]. Market Reactions and Stock Performance - On September 25, 2024, Jefferies downgraded Fortrea from Buy to Hold, citing weaknesses in the CRO model and a lack of real cost savings, leading to a stock drop of over 12% [5]. - On December 6, 2024, Baird Equity Research downgraded Fortrea to Neutral after the company canceled two conferences, resulting in an additional 8% decline in stock price [5]. - On March 3, 2025, Fortrea reported disappointing Q4 and full-year 2024 results, admitting that its revenue and EBITDA goals for 2025 were unrealistic, causing the stock to drop more than 25% [5].

Core Viewpoint - A class action lawsuit has been filed against Organon & Co. for allegedly misleading investors regarding its capital allocation strategy and dividend policies during the specified Class Period [1][3]. Group 1: Class Action Details - The class action represents investors who purchased Organon securities between November 3, 2022, and April 30, 2025 [1]. - Investors have until July 22, 2025, to file a lead plaintiff motion [1]. Group 2: Allegations Against Organon - The lawsuit claims that Organon concealed critical information about its capital allocation strategy, particularly regarding its quarterly dividend payout [3]. - Despite public statements indicating that maintaining the dividend was a top priority, Organon had adopted a debt reduction strategy that conflicted with this commitment [3]. - Following the acquisition of Dermavant Sciences Ltd., Organon intended to prioritize debt reduction, which led to a significant cut in its dividend [3]. Group 3: Financial Impact - On May 1, 2025, Organon announced a drastic reduction in its quarterly dividend from $0.28 to $0.02 per share [4]. - This announcement resulted in a stock decline of more than 27% [4].

Core Viewpoint - A class action lawsuit has been filed against Iovance Biotherapeutics, Inc. for misleading statements made during the Class Period from May 9, 2024, to May 8, 2025, which allegedly resulted in investor losses [1][3]. Group 1: Lawsuit Details - The lawsuit claims that Iovance made false or misleading statements regarding the initiation of patient treatments at newly authorized treatment centers (ATCs) [3]. - It is alleged that Iovance's sales team and ATCs faced challenges in effectively identifying and selecting patients, leading to higher patient drop-off rates [3]. - These operational issues reportedly resulted in increased costs and reduced revenue, as ATCs could not keep pace with product manufacturing [3]. - The lawsuit contends that the positive statements made by Iovance regarding its business and outlook were materially misleading or lacked a reasonable basis [3]. Group 2: Investor Actions - Investors who purchased Iovance securities during the Class Period have until July 14, 2025, to file a lead plaintiff motion [1]. - The Portnoy Law Firm is offering complimentary case evaluations to discuss options for recovering losses [2][4].